Search

Your search keyword '"B. Löbel"' showing total 6 results
Start Over Author "B. Löbel"
6 results on '"B. Löbel"'

1. Bone marrow transplantation and graft versus host disease (PP-077)

Author

H. Ueta, D. Sairafi, S. Ruhm, Y. Yang, Y. Sawanobori, M. Okas, D. Hashimoto, J. Plumas, A. Chybicka, A. Hidalgo, M. Li, F. Gabert, J. van den Brandt, K. Matsuno, M. Uzunel, J. Porwolik, S. Ikehara, S. Nava, M. Battista, Y. Cui, S. Yanai, K. Kärre, R. Wehner, J. Molens, M. Mielcarek, J. Gertow, X. Li, D. Drabczak-Skrzypek, O. Ringdèn, M. Shi, L. Chaperot, Q. Li, S. Mendez-Ferrer, D. Hannani, W. Lee, Y. Wang, K. Kalwak, J. Mattsson, R. Jenq, J. Theiss, N. Van Rooijen, D. Wehrum, M. Najar, J. Lange, B. Löbel, J. Owoc-Lempach, C. Prophete, X. Xu, Y. Kitazawa, P. S. Frenette, M. Schmitz, S. Chou, G. Liang, E. Gorczyńska, D. Dlubek, Y. Adachi, J. P. Tuckermann, M. Remberger, E. Jaskula, H. Karlsson, M. Ussowicz, S. Berglund, M. Bornhäuser, O. Hequet, M. Merad, Y. Chen, B. Rybka, R. Ryczan, D. Laurin, D. Lucas, A. Chow, M. Sall, H. M. Reichardt, S. Zhou, A. Lange, R. F. Olsson, M. Uhlin, H. Wang, and W. Chiang

Subjects
Pathology, medicine.medical_specialty, Graft-versus-host disease, Bone marrow transplantation, business.industry, Immunology, medicine, Immunology and Allergy, General Medicine, medicine.disease, business
Published
2010

2. Dendritic cells: function 2 (WS-024b)

Author

Erika Lamb, Yoshiya Tanaka, M. Bornhäuser, A. Iizuka, S. Bhatia, Noriyuki Sato, Rebekka Wehner, H. Yoshitani, Kazuhisa Nakano, K. Saito, K. Yamaoka, Izumi Sasaki, Nobuyuki Onai, Shruti Naik, Toshiaki Ohteki, K. Sun, K. Oshita, M. Hirokawa, A. Damavandy, Michael Bachmann, Yasmine Belkaid, K. Aoki, Katsuaki Hoshino, John R. Grainger, K. Maeshima, Lionel Feigenbaum, S. Miyatake, Elizabeth A. Wohlfert, Toshihiko Torigoe, Marc Schmitz, Tsuneyasu Kaisho, Jason A. Hall, B. Löbel, K. Okuya, T. Iguchi, Richard J. Hodes, Yasuaki Tamura, Kenichi Sawada, and H. Ohyagi

Subjects
Immunology, Immunology and Allergy, General Medicine, Function (mathematics), Biology, Neuroscience
Published
2010

3. Toll-like receptors (PP-001)

Author

D. J. Weisdorf, C. Svanborg, Q. Wang, P. Ekpo, D. Kim, M. Park, X. Liang, H. J. Kwak, D. Spencer, N. Srisamut, P. Datta, L. Bulat-Kardum, H. D. Ochs, F. E. Sepulveda, L. Song, A. Kariyone, M. Ogasawara, J. Jang, A. Junpee, K. Agematsu, D. R. Stach-Machado, H. Kariya, Daniela Verthelyi, K. Itoh, K. Yamazaki, W. Cheng, K. Miyake, S. Rezania, Q. Zhang, H. O. Bianchi, Y. Takeda, S. M. Kim, C. M. Blum, S. Ohta, J. C. Lee, F. Liu, M. E. Abdalsalam, Y. Sher, J. Cho, N. Nilsen, S. Das, J. Munz, K. A. Fitzgerald, Y. Jung, S. Hellmig, J. Inoue, W. W. Agace, C. Knetter, S. Sasawatari, F. Willems, T. Tomita, S. Akira, C. A. Palha De Sousa, C. L. Zawislak, D. Cole, P. Thuss-Patience, H. Jarmer, T. Espevik, F. Shokri, Ihsan Gursel, H. Yang, J. Seo, C. Gfell, D. H. Kim, J. N. Smith, X. Shen, F. Skjeldal, O. Bakke, E. P. Sgroe, A. Lennon-Dumenil, T. Hayashi, S. Rasmussen, S. Hong, I. Chung, J. Conlon, L. Cabanie, S. Gretschel, Y. Zhang, Y. Sakurai, S. Amigorena, M. Hattori, A. Ta, J. Zhang, H. An, R. A. Kurt, M. A. Zacks, M. Shirakawa, J. S. Rush, N. Parvizzadeh, M. Chen, J. Y. Kang, S. Kim, M. L. Salem, C. Yang, S. Maschalidi, O. Kumpf, X. Cao, J. S. Miller, O. Naga, D. Kanistanon, J. Lee, B. R. Blazar, Y. Liu, V. Flamand, D. Wakita, L. Grajkowska, Özlem Aslan, T. Seya, R. Lindblom, P. Abrahão, C. Ghirelli, N. M. Rachmawati, H. Oshiumi, L. Lu, U. Rungpanich, K. Inaba, E. Moseman, T. Nishimura, F. Piehl, B. Manoury, B. Nøhr Nielsen, T. Sasazuki, C. Lin, J. A. Hamerman, R. Colisson, T. Nakahama, T. Funasaka, W. Bae, A. Hasebe, K. McMichael, B. C. Cole, Y. Suda, G. A. Obando-Pereda, E. K. Ryu, R. F. Ashman, A. G. D. Bean, A. Wang, B. Bohle, F. Golsaz Shirazi, K. Chakraborty, K. Tosh, T. Olsson, V. Bachanova, P. Lenert, C. J. Kirschning, N. Toyama-Sorimachi, M. Kimoto, S. Paessler, D. Yoo, S. J. Oh, C. Kitzmüller, M. Schmitz, D. Baltzis, K. Ono, A. J. Karpala, L. Hamann, M. Matsumoto, J. Lou, Z. Kato, J. Tak, N. Amirmozzafari, A. T. Egunsola, L. HjerrildZeuthen, Y. Tsai, B. Löbel, D. Wang, M. V. Zeid-Kilani, E. Lien, H. E. Park, H. Liu, A. Kimura, L. Chang, N. Rashidi, N. Kondo, C. Ouyang, J. Wang, H. Fischer, E. K. Persson, M. Yadav, P. Tanthuvanit, J. K. Smith, S. Taki, N. J. Nilsen, V. Younesi, R. Mitamura, H. Jähnisch, I. Chinen, J. Chen, T. Kimura, E. Quivy, M. A. Farrar, N. Abdelmagid, P. Wongprompitak, H. Y. Kim, A H Zarnani, B. Uleng, O. Leo, R. W. Wong, H. Rabbani, Gizem Tincer, S. Bolliger, W. Huang, T. Miethke, D. Rodionov, L. Heslop, N. Makiuchi, O. Moussa, Y. Lee, S. Tanaka, M. S. Lee, M. Hashimoto, K. Takatsu, L. Tussey, H. Kitamura, M. Diez, C. Wang, J. Lum, J. Dutz, M. Puig, G. Robert, Y. Nagai, K. Masuko, S. Liu, W. Chen, M. Arjmand, Z. Dembic, C. Scheibenbogen, H. Weng, T. Matsunaga, Y. Maru, S. Daum, M. Ikutani, Y. Tang, M. Mosallaei, S. Ye, H. Husebye, H. Nikzamir, S. Bauer, E. Yang, Ismail Simsek, Y. Deng, H. Frøkiær, H. Kao, G. Weiss, A. L. Poussard, G. E. Etokebe, R. R. Schumann, H. H. Mu, I. Choi, S. Deifl, K. Masuda, M. Montero-Diaz, T. Kishimoto, M. Yao, U. Kavita, E. Latz, N. E. Yun, H. Ohnishi, C. Leng, J. Knezevic, Q. Yuan, L. Katoozian, S. Koizumi, Y. Aoyagi, A. M. Crespo, S. Takao, A. P. Makrigiannis, R. Wehner, D. Bitchev, P. Chong, S. Nuchprayoon, H. S. Koh, J. W. Lowenthal, S. Chiou, S. Watanabe, R. Zhong, M. Yoshizaki, G. P. Garlet, H. Poo, H. Geng, T. Böldicke, D. Torres, J. Khoshnoodi, H. Chen, U. McKeever, S. Miranda-Hernandez, S. Mutschlechner, J. Goeken, S. Umlauf, H. Tochio, B. Weaver, S. Delbauve, M. Yousefi, J. R. Ribeiro dos Reis, K. Fukudome, K. Harnesk, N. K. Yee, G. Rivell, Seda Yerlikaya, E. Lüdeking, J. Y. Kim, N. Tsuneyoshi, A. Chou, H. Li, G. Liu, H. Tsukamoto, X. Liu, A. Hise, N. Li, P. Cohen, Fuat Cem Yagci, and E. Jaensson

Subjects
biology, Toll, Immunology, biology.protein, Immunology and Allergy, General Medicine, Receptor, Cell biology
Published
2010

4. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells.

Author

Wehner R, Löbel B, Bornhäuser M, Schäkel K, Cartellieri M, Bachmann M, Rieber EP, and Schmitz M

Subjects
Antigens, CD biosynthesis, Antigens, Differentiation, T-Lymphocyte biosynthesis, Cytokines metabolism, Dendritic Cells cytology, Humans, Interferon-gamma metabolism, Interleukin-10 metabolism, Interleukin-12 metabolism, K562 Cells, Lectins, C-Type, Leukocytes, Mononuclear cytology, Lipopolysaccharides metabolism, Lymphocyte Activation, Models, Biological, Tumor Necrosis Factor-alpha metabolism, Amino Sugars metabolism, Dendritic Cells metabolism, Killer Cells, Natural metabolism
Abstract

Dendritic cells (DCs) display an extraordinary capacity to induce T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Additional findings indicate that DCs may also play a crucial role for the activation of natural killer (NK) cells, which are important effectors in innate antitumor immunity. However, studies investigating the interaction between native human DCs and NK cells are limited. Recently, we defined 6-sulfo LacNAc (slan) DCs as a major subpopulation of myeloid human blood DCs, which represent principal producers of the proinflammatory cytokines tumor necrosis factor-alpha and interleukin (IL)-12. Functional data revealed that slanDCs efficiently induce neoantigen-specific CD4+ T cells and activate tumor-reactive cytotoxic T cells. When evaluating the crosstalk between slanDCs and NK cells in this study, we found that lipopolysaccharide (LPS)-activated slanDCs efficiently enhance NK cell CD69 expression and interferon (IFN)-gamma secretion. NK cell-mediated tumor-directed cytotoxicity was significantly improved by slanDCs. NK cell activation induced by slanDCs was critically dependent on IL-12. When investigating the impact of NK cells on the immunostimulatory capacity of slanDCs, we observed that they promote DC maturation. In addition, NK cells strongly enhanced the secretion of immunomodulatory IL-12 and reduced the release of immunosuppressive IL-10 by slanDCs. IFN-gamma and cell-to-cell contact contributed to these effects. Furthermore, data revealed that DC-NK cell crosstalk improves slanDC-mediated differentiation of naïve CD4+ T lymphocytes into IFN-gamma-producing Th1 cells. In conclusion, we demonstrate a reciprocal activating interaction between slanDCs and NK cells, which may play a pivotal role in the regulation of antitumor immunity., (Copyright (c) 2008 Wiley-Liss, Inc.)

Published
2009
Full Text
View/download PDF

5. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.

Author

Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig K, Rieber EP, and Wirth MP

Subjects
Aged, Antigens, Surface analysis, Antigens, Surface immunology, CD8-Positive T-Lymphocytes immunology, Cancer Vaccines administration & dosage, Drug Resistance, Neoplasm, Glutamate Carboxypeptidase II analysis, Glutamate Carboxypeptidase II immunology, HLA-A Antigens chemistry, HLA-A Antigens immunology, HLA-A2 Antigen, Humans, Immunoenzyme Techniques, Immunomagnetic Separation, Immunotherapy, Active, Inhibitor of Apoptosis Proteins, Male, Membrane Proteins analysis, Membrane Proteins immunology, Microtubule-Associated Proteins analysis, Microtubule-Associated Proteins immunology, Middle Aged, Neoplasm Proteins analysis, Neoplasm Proteins immunology, Prostate-Specific Antigen blood, Prostatic Neoplasms pathology, Survivin, TRPM Cation Channels analysis, TRPM Cation Channels immunology, Cancer Vaccines therapeutic use, Dendritic Cells immunology, HLA-A Antigens therapeutic use, Prostatic Neoplasms immunology, Prostatic Neoplasms therapy
Abstract

Background: Immunotherapies might represent promising alternatives for the treatment of patients with hormone-refractory prostate cancer (HRPC). In a Phase I clinical trial, we evaluated a vaccination with dendritic cells (DCs) loaded with a cocktail consisting of HLA-A*0201-restricted peptides derived from five different prostate cancer-associated antigens [prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), survivin, prostein, transient receptor potential p8 (trp-p8)]., Methods: Eight HRPC patients received a total of four vaccinations every other week. Clinical and immunological responses were monitored by the determination of the serum PSA levels and by enzyme linked immunospot (ELISPOT) analyses, respectively., Results: Apart from local skin reactions no side effects were noted. One patient displayed a partial response (PR; PSA decrease >50%) and three other patients showed stable PSA values or decelerated PSA increases. In ELISPOT analyses, three of four PSA responders also showed antigen-specific CD8+ T-cell activation against prostein, survivin, and PSMA., Conclusions: The described protocol represents a safe and feasible concept for the induction of clinical and immunological responses. The application of a peptide cocktail-derived from different antigens as a novel treatment modality is supposed to allow for the genetic and biologic heterogeneity of PCa.

Published
2006
Full Text
View/download PDF

6. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.

Author

Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, and Bornhäuser M

Subjects
Adult, CD8-Positive T-Lymphocytes immunology, Cell Differentiation immunology, Dendritic Cells cytology, Female, Flow Cytometry, Humans, Immunity, Cellular, Immunomagnetic Separation, Interferon-gamma immunology, Interferon-gamma metabolism, Ligands, Lipopolysaccharide Receptors metabolism, Male, Middle Aged, Monocytes cytology, Monocytes immunology, Monocytes metabolism, Peptides immunology, Peptides therapeutic use, Cancer Vaccines immunology, Carcinoembryonic Antigen immunology, Colorectal Neoplasms therapy, Dendritic Cells immunology, Lung Neoplasms therapy
Abstract

Purpose: Dendritic cells (DCs) are characterized by their extraordinary capacity to induce T-cell responses, providing the opportunity of DC-based cancer vaccination protocols. In the present study, we conducted a phase I/II clinical trial to determine the capability of DCs differentiated from immunomagnetically isolated CD14+ monocytes and pulsed with a carcinoembryonic antigen-derived altered peptide (CEAalt) to induce specific CD8+ T cells in cancer patients., Experimental Design: Nine patients with CEA-positive colorectal cancer (n=7) or lung cancer (n=2) were enrolled in this study. Autologous CD14+ monocytes were isolated by large-scale immunomagnetic separation and differentiated to mature DCs in sufficient numbers and at high purity. After incubation with the CEAalt peptide and keyhole limpet hemocyanin, DCs were administered to patients intravenously at dose levels of 1 x 10(7) and 5 x 10(7) cells. Patients received four immunizations every second week., Results: ELISPOT analysis revealed a vaccine-induced increase in the number of CEAalt peptide-specific Interferon (IFN)-gamma producing CD8+ T cells in five of nine patients and of CD8+ T lymphocytes recognizing the native CEA peptide in three of nine patients. In addition, CD8+ T lymphocytes derived from one patient exhibiting an immunological response after vaccination efficiently lysed peptide-loaded T2 cells and tumor cells. Immunization was well tolerated by all patients without severe signs of toxicity., Conclusion: Vaccination with CEAalt-pulsed DCs derived from immunomagnetically isolated CD14+ monocytes efficiently expand peptide-specific CD8+ T lymphocytes in vivo and may be a promising alternative for cancer immunotherapy.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results